Lombard Medical Technologies PLC Intention to pursue a US IPO and NASDAQ listing (1361X)

TIDMLMT

RNS Number : 1361X

Lombard Medical Technologies PLC

08 January 2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Lombard Medical Technologies PLC

("Lombard Medical" or "the Company")

Lombard Medical announces intention to pursue a US IPO

and NASDAQ listing of ordinary shares

London, UK, 8 January, 2014 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on Endovascular Aortic Repair ("EVAR") of abdominal aortic aneurysms ("AAAs"), today announces that it intends to submit a registration statement to the US Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of ordinary shares and a listing on NASDAQ ("NASDAQ IPO").

Lombard Medical has appointed Jefferies LLC ("Jefferies") and Barclays Capital Inc. ("Barclays") as financial advisors in relation to the overall transaction, including the Share Exchange, and as joint bookrunners in connection with the proposed NASDAQ IPO.

To facilitate the NASDAQ IPO, a new Cayman Islands holding company will be created and existing shares in Lombard Medical will be exchanged for new shares in the holding company ("Share Exchange").

Commencement of the initial public offering is conditional upon completion of the SEC review process with respect to the registration statement and is subject to market conditions and other considerations. In connection with the NASDAQ IPO, Lombard Medical will also delist its ordinary shares from AIM, a market of the London Stock Exchange.

In the Share Exchange, existing shareholders will receive shares in the new Cayman Islands holding company in exchange for the shares they hold in Lombard Medical. These new shares will not be admitted to trading on AIM. Shareholders will need to consider their ability to hold and trade NASDAQ listed shares following the AIM delisting. Full details of the proposals will be set out in a circular to shareholders in due course.

Lombard Medical intends to use proceeds from the NASDAQ IPO to accelerate its commercialization strategy for Aorfix(TM) in the US with a particular focus on continuing to build its direct sales force and marketing infrastructure as well as continuing to invest in developing new products to treat complex vascular disease, including a stent graft to treat aneurysms in the thoracic aorta.

Simon Hubbert, Chief Executive Officer of Lombard Medical, commented. "The Board believes that the proposed listing on NASDAQ is in the best interests of shareholders as we seek to align our place of listing with the largest and most important market for the Company's products. A US listing will provide access to a larger pool of investors with a deep understanding of the healthcare market in which the Company operates. We look forward to joining the significant number of medical technology companies that trade on NASDAQ."

The Company received United States Food and Drug Administration ("US FDA") approval for Aorfix in February 2013 with a unique label indication for the treatment of patients with angulations at the neck of the aneurysm up to and including 90 degrees, and formally launched Aorfix in the US in November 2013.

The global AAA market for EVAR devices is estimated to be approximately $1.4 billion. The US market is estimated to be worth around half of the global market and is expected to grow at a compound annual growth rate in excess of 7 percent over the next 5 years, driven largely by the growth of the ageing population and patient screening programs. In addition, introduction of new technologies such as Aorfix, which allow more patients to receive endovascular treatment of AAA disease, could potentially expand the market further.

This press release and the information it contains is not for publication or distribution, directly or indirectly, in or into the United States. This press release is not intended to, and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

-Ends-

For further information:

 
 Lombard Medical Technologies PLC       Tel: [phone] 
  Simon Hubbert, Chief Executive 
  Officer 
  Ian Ardill, Chief Financial Officer 
 
 Jefferies LLC 
  Henry Elphick / David Weaver            Tel: [phone] 
  Michael Robinson                        Tel: [phone] 
 
 Barclays Capital Inc                   Tel: [phone] 
  Doug Solomon / Joe Lombardo 
 
 Canaccord Genuity Limited (Nomad)      Tel: [phone] 
  Lucy Tilley / Tim Redfern / Henry 
  Fitzgerald O'Connor / Dr Julian 
  Feneley 
 
 FTI Consulting (UK)                    Tel: [phone] 
  Simon Conway / Stephanie Cuthbert 
  / Victoria Foster Mitchell 
 
 Allen & Caron (US)                       Tel: [phone] 
  Matt Clawson 
 
 

About Abdominal Aortic Aneurysms

AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year over 500,000 new cases are diagnosed. In the US, aortic aneurysm disease is among the leading causes of death and it is estimated that 1.7 million people over the age of 55 have an abdominal aortic aneurysm.

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company focused on device solutions for the $1.4 billion per annum abdominal aortic aneurysm ("AAA") repair market. The Company's lead product, Aorfix(TM), is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy, which is often present in advanced AAA disease. Aorfix is the only stent graft approved for AAA neck angulations of up to 90 degrees and is currently being commercialized worldwide. Aorfix is the first AAA stent graft not of US origin to gain US FDA approval. The Company is headquartered in Oxfordshire, England with US operations in Irvine, CA.

Further background on the Company can be found at www.lombardmedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCMMGGMGRDGDZG